Lung cancers with hypoxia-driven plasticity also represent promising candidates: exosomal miR-210 derived from lung CSCs promotes metastasis, while neuroendocrine-lineage lung tumors, including subtypes of small-cell lung cancer (SCLC), may likewise be considered for RAX-targeted interventions, although tumor type-specific validation remains essential [185]. The gene discussed is RAX; the disease is small cell lung carcinoma.